Effect of food on the pharmacokinetics of the WEE1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors

被引：0
|
作者：
Mats Någård
Mei-Lin Ah-See
Karen So
Marit Vermunt
Fiona Thistlethwaite
Mariette Labots
Patricia Roxburgh
Alain Ravaud
Mario Campone
Liselot Valkenburg-van Iersel
Lone Ottesen
Yan Li
Ganesh Mugundu
机构：
[1] R&D Clinical Pharmacology and Safety Sciences,Clinical Pharmacology and Quantitative Pharmacology
[2] AstraZeneca,Late Stage Development, Oncology R&D
[3] AstraZeneca,Clinical Pharmacology Biologics and Bioanalysis, Clinical Pharmacology and Safety Science, BioPharmaceuticals R&D
[4] The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital,Clinical Pharmacology and Quantitative Pharmacology, R&D Clinical Pharmacology and Safety Sciences
[5] The Christie NHS Foundation Trust and University of Manchester,undefined
[6] Cancer Center Amsterdam,undefined
[7] Amsterdam UMC,undefined
[8] Beaston West of Scotland Cancer Centre and University of Glasgow,undefined
[9] Bordeaux University Hospital,undefined
[10] ICO – Site René,undefined
[11] Maastricht University Medical Centre,undefined
[12] AstraZeneca,undefined
[13] AstraZeneca,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2020年 / 86卷
关键词：
Adavosertib; Food effect; Pharmacokinetics; Oncology; WEE1;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：97 / 108
页数：11
相关论文
共 50 条
  • [31] PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer
    Jhuraney, Ankita
    Woods, Nicholas T.
    Wright, Gabriela
    Rix, Lily
    Kinose, Fumi
    Kroeger, Jodi L.
    Remily-Wood, Elizabeth
    Cress, W. Douglas
    Koomen, John M.
    Brantley, Stephen G.
    Gray, Jhanelle E.
    Haura, Eric B.
    Rix, Uwe
    Monteiro, Alvaro N.
    MOLECULAR CANCER THERAPEUTICS, 2016, 15 (07) : 1669 - 1681
  • [32] Strategies for Targeted Therapy in Head and Neck Squamous Cell Carcinoma Using WEE1 Inhibitor AZD1775
    Kao, Michael
    Green, Carlos
    Sidorova, Julia
    Mendez, Eduardo
    JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2017, 143 (06) : 631 - 633
  • [33] DNA damage response and therapeutic activity following once-daily administration of the Wee 1 inhibitor AZD1775 (adavosertib)
    Mittra, Arjun
    Coyne, Geraldine O'Sullivan
    Kummar, Shivaani
    Do, Khanh
    Bruns, Ashley
    Juwara, Lamin
    Piekarz, Richard
    Rubinstein, Larry
    Prindiville, Sheila
    Sharon, Elad
    Streicher, Howard
    Hsia, Tiffaney
    Mugundu, Ganesh
    Ji, Jiuping
    Wilsker, Deborah
    Dull, Angie B.
    Miller, Brandon
    Kinders, Robert J.
    Parchment, Ralph
    Doroshow, James H.
    Chen, Alice P.
    Takebe, Naoko
    CANCER RESEARCH, 2019, 79 (13)
  • [34] Antitumor effects of WEE1 inhibitor, AZD1775 alone or in combination with PARP inhibitor in triple negative breast cancer cells
    Ha, Dong Hyeon
    Min, Arrum
    Kim, Seongyeong
    Kim, So Hyeon
    Jang, Hyemin
    Kim, Yu Jin
    Jung, Daeun
    Park, YoonJung
    Suh, Koung Jin
    Lee, Kyung-Hun
    Kim, Tae-Yong Kiim
    Im, Seock-Ah
    CANCER RESEARCH, 2018, 78 (13)
  • [35] Adavosertib (AZD1775) does not prolong the QTc interval in patients with advanced solid tumors: a phase I open-label study
    Mats Någård
    Mei-Lin Ah-See
    James Strauss
    Trisha Wise-Draper
    Howard P. Safran
    Laura Nadeau
    William J. Edenfield
    Lionel D. Lewis
    Dinko Rekić
    Corina Dota
    Lone H. Ottesen
    Yan Li
    Ganesh M. Mugundu
    Cancer Chemotherapy and Pharmacology, 2023, 92 : 141 - 150
  • [36] Adavosertib (AZD1775) does not prolong the QTc interval in patients with advanced solid tumors: a phase I open-label study
    Nagard, Mats
    Ah-See, Mei-Lin
    Strauss, James
    Wise-Draper, Trisha
    Safran, Howard P.
    Nadeau, Laura
    Edenfield, William J.
    Lewis, Lionel D.
    Rekic, Dinko
    Dota, Corina
    Ottesen, Lone H.
    Li, Yan
    Mugundu, Ganesh M.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2023, 92 (02) : 141 - 150
  • [37] The Combination of the PARP Inhibitor Olaparib and the WEE1 Inhibitor AZD1775 as a New Therapeutic Option for Small Cell Lung Cancer
    Lallo, Alice
    Frese, Kristopher K.
    Morrow, Christopher J.
    Sloane, Robert
    Gulati, Sakshi
    Schenk, Maximillian W.
    Trapani, Francesca
    Simms, Nicole
    Galvin, Melanie
    Brown, Stewart
    Hodgkinson, Cassandra L.
    Priest, Lynsey
    Hughes, Adina
    Lai, Zhongwu
    Cadogan, Elaine
    Khandelwal, Garima
    Simpson, Kathryn L.
    Miller, Crispin
    Blackhall, Fiona
    O'Connor, Mark J.
    Dive, Caroline
    CLINICAL CANCER RESEARCH, 2018, 24 (20) : 5153 - 5164
  • [38] Wee1 Inhibitor AZD1775 Effectively Inhibits the Malignant Phenotypes of Esophageal Squamous Cell Carcinoma In Vitro and In Vivo
    Bi, Shuning
    Wei, Qiuren
    Zhao, Zhijun
    Chen, Liang
    Wang, Chaojie
    Xie, Songqiang
    FRONTIERS IN PHARMACOLOGY, 2019, 10
  • [39] Phase I study of definitive chemoradiation with gemcitabine and the WEE1 inhibitor AZD1775 in unresectable pancreatic cancer.
    Cuneo, Kyle Clifford
    Morgan, Meredith
    Schipper, Matthew J.
    Maybaum, Jonathan
    Al-Hawary, Mahmoud
    Simeone, Diane M.
    Sahai, Vaibhav
    Zalupski, Mark
    Lawrence, Theodore Steven
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [40] Strategic Development of AZD1775, a Wee1 Kinase Inhibitor, for Cancer Therapy (vol 27, pg 741, 2018)
    Fu, S.
    Wang, Y.
    Keyomarsi, K.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2019, 28 (03) : 297 - 297
12345